Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients
复制标题
阿巴西普治疗日本类风湿关节炎患者的临床疗效
DOI：
10.1007/s10165-012-0760-4
复制
发表时间：
2013
期刊：
影响因子：
2.2
通讯作者：
Yoshio
中科院分区：
文献类型：
--
作者：
Takahashi N;Kojima T;Kaneko A;Kida D;Hirano Y;Fujibayashi T;Yabe Y;Takagi H;Oguchi T;Miyake H;Kato T;Fukaya N;Ishikawa H;Hayashi M;Tsuboi S;Kanayama Y;Kato D;Funahashi K;Matsubara H;Hattori Y;Hanabayashi M;Hirabara S;Terabe K;Yoshio
ObjectivesThe purpose of this study is to examine the treatment retention and efficacy of abatacept，the first member of a new class of biological agents，in Japanese rheumatoid arthritis（RA）patients during clinical practice.MethodsA retrospective multicenter study was conducted with patients who undergoed abatacept therapy for 24 wk（n= 143）.ResultsPatients at baseline have a mean age of 63.5 years，平均疾病持续时间为11.3年，28个关节的平均疾病活动性评分（DAS 28）为4.5。阿巴西普治疗的总体保留率在24周时为83.2%，此时46.2%的患者达到DAS 28定义的低疾病活动度（LDA; DAS 28 <3.2），26.6%的患者达到DAS 28定义的缓解（DAS 28 <2.6）。与既往接受过生物制剂治疗的患者相比，既往未接受过生物制剂治疗的患者达到LDA的比例显著更高（60.9% vs. 34.2%，p= 0.001）。有或没有伴随甲氨蝶呤（MTX）治疗的患者之间没有显着差异（45.2与47.5%）。ConclusionsAbatacept治疗RA的临床治疗过程中似乎是非常有效的，耐受性良好。阿巴西普在没有生物制剂使用史的患者中特别有效，并且似乎不依赖于伴随的MTX治疗。
ObjectivesThe purpose of this study was to examine the treatment retention and efficacy of abatacept, the first member of a new class of biologic agents, in Japanese rheumatoid arthritis (RA) patients during clinical practice.MethodsA retrospective multicenter study was conducted with patients who underwent abatacept therapy for 24 weeks (n= 143).ResultsPatients at baseline had a mean age of 63.5 years, a mean disease duration of 11.3 years, and a mean disease activity score in 28 joints (DAS28) of 4.5. Overall retention of abatacept treatment was 83.2 % at 24 weeks, when 46.2 % of patients achieved DAS28-defined low disease activity (LDA; DAS28 <3.2) and 26.6 % achieved DAS28-defined remission (DAS28 <2.6). LDA was achieved in a significantly higher proportion of patients without prior biologics therapy compared to those with prior biologics (60.9 vs. 34.2 %,p= 0.001). There was no significant difference between patients with or without concomitant methotrexate (MTX) therapy (45.2 vs. 47.5 %).ConclusionsAbatacept therapy appears to be highly effective and well tolerated during clinical treatment of RA. Abatacept was particularly effective in patients with no history of biologics use, and did not appear to be dependent on concomitant MTX therapy.